Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -217.64x is 38% above its 1-year average of -353.49x, near the high end of its 1-year range (-432.65x–-217.64x).
As of the fiscal period ended Thursday, September 30, 2021. 38.43% above its 12-month average of -353.49x.
Reported quarterly interest coverage; no daily interpolation. Q3 FY2021 (2021-09-30): -217.64x.
INTEREST COVERAGE RATIO
-217.64x
INTEREST COVERAGE RATIO AVG TTM
-353.49x
INTEREST COVERAGE RATIO AVG 3Y
N/A
INTEREST COVERAGE RATIO AVG 5Y
N/A
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+38.43%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-6.44x
median of 527 covered companies
CURRENT VS SECTOR MEDIAN
-3279.45%
vs the sector median at left
Entrada Therapeutics, Inc.
Market Cap
$210.41M
Interest Coverage Ratio
-217.64x
TTM Avg
-353.49x
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$209.91M
Interest Coverage Ratio
N/A
TTM Avg
39.15x
3Y Avg
39.15x
5Y Avg
39.15x
Market Cap
$210.98M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$208.31M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$207.27M
Interest Coverage Ratio
16.00x
TTM Avg
14.45x
3Y Avg
13.14x
5Y Avg
13.02x
Market Cap
$214.24M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.46M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$205.80M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$215.07M
Interest Coverage Ratio
N/A
TTM Avg
1274.61x
3Y Avg
1274.61x
5Y Avg
1274.61x
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | $210.41M | -217.64x | -353.49x | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $209.91M | N/A | 39.15x | 39.15x | 39.15x |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | N/A | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 16.00x | 14.45x | 13.14x | 13.02x |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | N/A | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | N/A | N/A | N/A | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | N/A | 1274.61x | 1274.61x | 1274.61x |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | N/A | N/A | N/A | N/A |
Interest Coverage
-217.6x
Debt/Equity
0.21
Current Ratio
10.89
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2021-09-30 | -217.64x |
| 2020-12-31 | -432.65x |
| 2020-09-30 | -410.18x |
